Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2012

View Archived Issues

Proof-of-concept study begins with gevokizumab in acute coronary syndrome

InSite Vision completes enrollment in phase III BromSite study

Japanese group divulges new antibacterial agents

New hPASK/CK II inhibitors synthesized by Bioenergenix

Researchers at Novartis synthesize new CYP17 inhibitors

New TGR5 receptor agonists prepared by Bristol-Myers Squibb

GDC-0449 evaluated for new indication

Actinium Pharmaceuticals and Philogen begin development of Ac-225 labeled antibody

OPKO Health receives research grants from Mexican government

Priority review awarded for Eisai's NDA for new formulation of AcipHex

Taisho and Novartis sign agreement for diabetes treatment candidate in Japan

Viralytics reports preliminary data from research conducted with University of Surrey

Roche patents novel D3/5-HT2A receptor ligands

University of Sydney discloses novel agents isolated from propolis

New targets identified for malignant peripheral nerve sheath tumors

VR Laboratories selects new rhinovirus therapeutic

Ghent University and MDxHealth establish new epigenomics center

FDA posts Vibativ advisory committee briefing documents

Cytokinetics reports phase IIa tirasemtiv trial data

Lipid-core peptides may have efficacy as helminth vaccines

Experimental gene therapy approaches for the treatment of drug-resistant epilepsy

Cyclin-dependent kinase 6 as a target in medulloblastoma

Novel murine model of proteinuria developed at Washington University

BioCryst Pharmaceuticals and Presidio Pharmaceuticals end merger

Alimera Sciences develops patient access scheme for Iluvien in U.K.

Boston Scientific commences patient enrollment in EVOLVE II trial of Synergy stent system

Cel-Sci updates on phase III Multikine immunotherapy trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...